Immuneering Corporation (IMRX)
NASDAQ: IMRX · Real-Time Price · USD
6.40
-0.29 (-4.33%)
At close: Dec 5, 2025, 4:00 PM EST
6.42
+0.02 (0.31%)
After-hours: Dec 5, 2025, 7:41 PM EST
Immuneering Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
66
Market Cap
413.25M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
IMRX News
- 10 days ago - Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire
- 23 days ago - Immuneering Corporation (IMRX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 23 days ago - Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates - GlobeNewsWire
- 4 weeks ago - Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025 - GlobeNewsWire
- 2 months ago - Immuneering Corporation - Special Call - Seeking Alpha
- 2 months ago - Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025 - GlobeNewsWire
- 2 months ago - Immuneering: Positive Pancreatic Cancer Data Atebimetinib Leads To Q4 2025 Catalyst - Seeking Alpha
- 2 months ago - Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi - GlobeNewsWire